Skip to Main Content

Paper Details

Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.
Am J Hematol
18
2021
STAT3, chronic lymphocytic leukemia, pyrimethamine
Author NameAffiliation
Svitlana TyekuchevaDana-Farber Cancer Institute
Michael XiangDana-Farber Cancer Institute
Catherine J WuDana-Farber Cancer Institute
Catherine J WuBrigham and Women's Hospital and Harvard Medical School
  • 1 - 4

Datasets

Release 1.2